Evidence map›Paper›PMID 25622776›Full record

Trial reportDrug and alcohol dependence2015

Using behavioral economics to predict opioid use during prescription opioid dependence treatment.

Matthew J Worley, Steven J Shoptaw, Warren K Bickel, Walter Ling

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Behavioral economic predictors of brief alcohol intervention outcomes.Journal of consulting and clinical psychology · 2015
    Trial
  3. Article
  4. A hypothetical lottery task to assess relative resource allocation toward alcohol and cannabis.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2023
    Article
  5. Behavioral economic indicators of risky drinking among community-dwelling emerging adults.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2021
    Article
  6. The role of reward and reinforcement in understanding alcohol use among adults living with HIV in South Africa.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew J WorleyDepartment of Family Medicine, University of California, Los Angeles, 10880 Wilshire Boulevard, Suite 1800, Los Angeles, CA 90024, United States. Electronic address: mworley@mednet.ucla.edu.
Steven J ShoptawDepartment of Family Medicine, University of California, Los Angeles, 10880 Wilshire Boulevard, Suite 1800, Los Angeles, CA 90024, United States.
Warren K BickelAddiction Recovery Research Center (ARRC), Virginia Tech Carillion Research Institute, 2 Riverside Circle, Roanoke, VA 24016, United States.
Walter LingIntegrated Substance Abuse Program, University of California, Los Angeles, 1640 S. Sepulveda, Ste. 120, Los Angeles, CA 90024, United States.
University of California, Los Angeles · USVirginia Tech · US

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
CLINICAL TRIAL RESEARCH PROJECT COREU10DA020036 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DALEY, DENNIS C · 2005 to 2015
$14.1M
Randomized Trial of Ibudilast for Methamphetamine DependenceR01DA035054 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEINZERLING, KEITH GREGORY · 2012 to 2017
$3.3M
Varenicline for Methamphetamine DependenceR01DA030577 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2011 to 2013
$1.8M
UCLA Training Program on Addiction Medicine in Primary CareT32DA026400 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2009 to 2013
$1.3M
NIDA NIH HHS 2U10DA013035NIDA NIH HHS 2U10DA013045NIDA NIH HHS 2U10DA013714NIDA NIH HHS 2U10DA013727NIDA NIH HHS 2U10DA015815NIDA NIH HHS 2U10DA015831NIDA NIH HHS 2U10DA020036NIDA NIH HHS 3U10DA01304NIDA NIH HHS 5R01 DA030577NIDA NIH HHS 5R01 DA035054NIDA NIH HHS 5T32DA026400NIDA NIH HHS 5U10DA013732NIDA NIH HHS L30 DA038321NIDA NIH HHS R01 DA030577NIDA NIH HHS R01 DA035054NIDA NIH HHS T32 DA026400NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA020036NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundResearch grounded in behavioral economics has previously linked addictive behavior to disrupted decision-making and reward-processing, but these principles have not been examined in prescription opioid addiction, which is currently a major public health problem. This study examined whether pre-treatment drug reinforcement value predicted opioid use during outpatient treatment of prescription opioid addiction.

methodsSecondary analyses examined participants with prescription opioid dependence who received 12 weeks of buprenorphine-naloxone and counseling in a multi-site clinical trial (N=353). Baseline measures assessed opioid source and indices of drug reinforcement value, including the total amount and proportion of income spent on drugs. Weekly urine drug screens measured opioid use.

resultsObtaining opioids from doctors was associated with lower pre-treatment drug spending, while obtaining opioids from dealers/patients was associated with greater spending. Controlling for demographics, opioid use history, and opioid source frequency, patients who spent a greater total amount (OR=1.30, p<.001) and a greater proportion of their income on drugs (OR=1.31, p<.001) were more likely to use opioids during treatment.

conclusionsIndividual differences in drug reinforcement value, as indicated by pre-treatment allocation of economic resources to drugs, reflects propensity for continued opioid use during treatment among individuals with prescription opioid addiction. Future studies should examine disrupted decision-making and reward-processing in prescription opioid users more directly and test whether reinforcer pathology can be remediated in this population.

Indexed as

AdultAgedBuprenorphineBuprenorphine, Naloxone Drug CombinationEconomics, BehavioralFemaleHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPredictive Value of TestsPrescription Drug MisuseTreatment OutcomeBuprenorphineBuprenorphine, Naloxone Drug CombinationNaloxoneNarcotic AntagonistsBehavioral economicsBuprenorphine–naloxonePrescription opioidsTreatment outcome

Identifiers

PMID25622776
PMCPMC4666717
OpenAlexW2067521757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.